
Pubmed-entry ::= {
  pmid 29440309,
  medent {
    em std {
      year 2018,
      month 2,
      day 15,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive
 Impairments and Social Withdrawal in N-Methyl-d-Aspartate Receptor
 Antagonist-Induced Rat Models of Schizophrenia."
      },
      authors {
        names std {
          {
            name ml "Nakashima M",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan."
          },
          {
            name ml "Imada H",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan."
          },
          {
            name ml "Shiraishi E",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan."
          },
          {
            name ml "Ito Y",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan."
          },
          {
            name ml "Suzuki N",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan."
          },
          {
            name ml "Miyamoto M",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan."
          },
          {
            name ml "Taniguchi T",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan."
          },
          {
            name ml "Iwashita H",
            affil str "Neuroscience Drug Discovery Unit (M.N., H.Im., E.S.,
 Y.I., N.S., T.T., H.Iw.) and Drug Metabolism and Pharmacokinetics Research
 Laboratories (M.M.), Research, Takeda Pharmaceutical Company Limited,
 Fujisawa, Japan hiroki.iwashita@takeda.com."
          }
        }
      },
      from journal {
        title {
          iso-jta "J. Pharmacol. Exp. Ther.",
          ml-jta "J Pharmacol Exp Ther",
          issn "1521-0103",
          name "The Journal of pharmacology and experimental therapeutics"
        },
        imp {
          date std {
            year 2018,
            month 4
          },
          volume "365",
          issue "1",
          pages "179-188",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus received,
              date std {
                year 2017,
                month 10,
                day 5
              }
            },
            {
              pubstatus accepted,
              date std {
                year 2018,
                month 2,
                day 5
              }
            },
            {
              pubstatus pubmed,
              date std {
                year 2018,
                month 2,
                day 15,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2019,
                month 5,
                day 29,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2018,
                month 2,
                day 15,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 29440309,
        pii "jpet.117.245506",
        doi "10.1124/jpet.117.245506",
        other {
          db "ELocationID doi",
          tag str "10.1124/jpet.117.245506"
        }
      }
    },
    abstract "The pathophysiology of schizophrenia has been associated with
 glutamatergic dysfunction. Modulation of the glutamatergic signaling pathway,
 including N-methyl-d-aspartate (NMDA) receptors, can provide a new
 therapeutic target for schizophrenia. Phosphodiesterase 2A (PDE2A) is highly
 expressed in the forebrain, and is a dual substrate enzyme that hydrolyzes
 both cAMP and cGMP, which play pivotal roles as intracellular second
 messengers downstream of NMDA receptors. Here we characterize the in vivo
 pharmacological profile of a selective and brain-penetrant PDE2A inhibitor,
 (N-{(1S)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-
oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide) (TAK-915) as a novel
 treatment of schizophrenia. Oral administration of TAK-915 at 3 and 10 mg/kg
 significantly increased cGMP levels in the frontal cortex, hippocampus, and
 striatum of rats. TAK-915 at 10 mg/kg significantly upregulated the
 phosphorylation of alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid
 receptor subunit GluR1 in the rat hippocampus. TAK-915 at 3 and 10 mg/kg
 significantly attenuated episodic memory deficits induced by the NMDA
 receptor antagonist (+)-MK-801 hydrogen maleate (MK-801) in the rat passive
 avoidance test. TAK-915 at 10 mg/kg significantly attenuated working memory
 deficits induced by MK-801 in the rat radial arm maze test. Additionally,
 TAK-915 at 10 mg/kg prevented subchronic phencyclidine-induced social
 withdrawal in social interaction in rats. In contrast, TAK-915 did not
 produce antipsychotic-like activity; TAK-915 had little effect on MK-801- or
 methamphetamine-induced hyperlocomotion in rats. These results suggest that
 TAK-915 has a potential to ameliorate cognitive impairments and social
 withdrawal in schizophrenia.",
    mesh {
      {
        term "Animals"
      },
      {
        term "Antipsychotic Agents",
        qual {
          {
            subh "pharmacokinetics"
          },
          {
            subh "pharmacology"
          },
          {
            subh "therapeutic use"
          }
        }
      },
      {
        term "Avoidance Learning",
        qual {
          {
            subh "drug effects"
          }
        }
      },
      {
        term "Brain",
        qual {
          {
            subh "drug effects"
          },
          {
            subh "metabolism"
          },
          {
            subh "physiopathology"
          }
        }
      },
      {
        term "Cognitive Dysfunction",
        qual {
          {
            mp TRUE,
            subh "drug therapy"
          },
          {
            subh "etiology"
          },
          {
            subh "metabolism"
          },
          {
            subh "physiopathology"
          }
        }
      },
      {
        term "Cyclic AMP",
        qual {
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Cyclic GMP",
        qual {
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Cyclic Nucleotide Phosphodiesterases, Type 2",
        qual {
          {
            mp TRUE,
            subh "antagonists & inhibitors"
          }
        }
      },
      {
        term "Disease Models, Animal"
      },
      {
        term "Locomotion",
        qual {
          {
            subh "drug effects"
          }
        }
      },
      {
        term "Male"
      },
      {
        term "Memory, Episodic"
      },
      {
        term "Phosphodiesterase Inhibitors",
        qual {
          {
            subh "pharmacokinetics"
          },
          {
            mp TRUE,
            subh "pharmacology"
          },
          {
            subh "therapeutic use"
          }
        }
      },
      {
        term "Pyrazines",
        qual {
          {
            subh "pharmacokinetics"
          },
          {
            mp TRUE,
            subh "pharmacology"
          },
          {
            subh "therapeutic use"
          }
        }
      },
      {
        term "Pyridines",
        qual {
          {
            subh "pharmacokinetics"
          },
          {
            mp TRUE,
            subh "pharmacology"
          },
          {
            subh "therapeutic use"
          }
        }
      },
      {
        term "Rats"
      },
      {
        term "Receptors, AMPA",
        qual {
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Receptors, N-Methyl-D-Aspartate",
        qual {
          {
            mp TRUE,
            subh "antagonists & inhibitors"
          }
        }
      },
      {
        term "Schizophrenia",
        qual {
          {
            subh "chemically induced"
          },
          {
            mp TRUE,
            subh "complications"
          }
        }
      },
      {
        mp TRUE,
        term "Social Behavior"
      }
    },
    substance {
      {
        type nameonly,
        name "Antipsychotic Agents"
      },
      {
        type nameonly,
        name "Phosphodiesterase Inhibitors"
      },
      {
        type nameonly,
        name "Pyrazines"
      },
      {
        type nameonly,
        name "Pyridines"
      },
      {
        type nameonly,
        name "Receptors, AMPA"
      },
      {
        type nameonly,
        name "Receptors, N-Methyl-D-Aspartate"
      },
      {
        type nameonly,
        name "TAK-915"
      },
      {
        type cas,
        cit "E0399OZS9N",
        name "Cyclic AMP"
      },
      {
        type ec,
        cit "3.1.4.17",
        name "Cyclic Nucleotide Phosphodiesterases, Type 2"
      },
      {
        type cas,
        cit "H2D2X058MU",
        name "Cyclic GMP"
      },
      {
        type cas,
        cit "TFZ3H25BS1",
        name "glutamate receptor ionotropic, AMPA 1"
      }
    },
    pmid 29440309,
    pub-type {
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    },
    status medline
  }
}


